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in Trans-ethnic Fine-Mapping Studies
Gleb Kichaev1 and Bogdan Pasaniuc1,2,3,*
Localization of causal variants underlying known risk loci is one of the main research challenges following genome-wide association
studies. Risk loci are typically dissected through fine-mapping experiments in trans-ethnic cohorts for leveraging the variability in
the local genetic structure across populations. More recent works have shown that genomic functional annotations (i.e., localization
of tissue-specific regulatory marks) can be integrated for increasing fine-mapping performance within single-population studies.
Here, we introduce methods that integrate the strength of association between genotype and phenotype, the variability in the genetic
backgrounds across populations, and the genomic map of tissue-specific functional elements to increase trans-ethnic fine-mapping ac-
curacy. Through extensive simulations and empirical data, we have demonstrated that our approach increases fine-mapping resolution
over existing methods. We analyzed empirical data from a large-scale trans-ethnic rheumatoid arthritis (RA) study and showed that the
functional genetic architecture of RA is consistent across European and Asian ancestries. In these data, we used our proposedmethods to
reduce the average size of the 90% credible set from 29 variants per locus for standard non-integrative approaches to 22 variants.Introduction
Genome-wide associations studies (GWASs) have reproduc-
ibly identified thousands of risk loci associated with com-
plex traits and diseases.1–7 Unfortunately, the index vari-
ants reported in these studies are typically not biologically
causal but rather correlated with the underlying causal
variant through linkage disequilibrium (LD).8 Fine-map-
ping experiments identify causal variants responsible for
the GWAS signal first by gathering dense genetic informa-
tion, either through targeted sequencing or dense imputa-
tion, and second by statistically prioritizing variants that
can subsequently be validated in functional studies.3,6,9,10
Divergent population histories due to various demo-
graphic forces such as bottlenecks and expansions have
produced unique genomic landscapes across ethnic-
ities.11,12 Such differences in LD patterns and variant fre-
quencies across populations can increase the power of sta-
tistical fine mapping if they are properly modeled.3,13–18
Intuitively, if a locus contains a causal variant, the neigh-
borhood of LD partners linked to this variant will be
distinct in different populations. Thus, aggregating the
strength of association across multiple populations might
accentuate the signal from the true causal variant(s) while
dampening the noise from correlated variants.
A common approach to combining information across
multiple studies is through inverse-variance fixed-effects
meta-analysis,19 which assumes that effect sizes of causal
variants are similar across studies or populations. This
assumption can be relaxed by a random-effects strategy,
although it has been observed that this usually results in
a decrease in statistical power.20 A recent, and more robust,
Bayesian meta-analysis framework15 was proposed to
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and the Bayes factors supplied by the latter approach can
be readily converted into posterior probabilities of associa-
tion (PPAs) for the construction of fine-mapping credible
sets.3,21 However, these credible sets are commonly built
under the assumption that a locus harbors at most a single
causal variant,3,22–24 which might be invalidated at many
risk loci,17,25,26 leading to miscalibrated credible sets.27,28
Although conceptually it might be possible to create cred-
ible sets on the basis of independent signals identified
through conditional analysis, this strategy suffers from
necessitating an ad hoc re-definition of the fine-mapping
region. Furthermore, multiple causal variants in LD can
create at neighboring sites synthetic associations that are
potentially stronger than the association at the true causal
variants. The iterative conditioning strategy would neces-
sarily select these synthetic SNPs first, thereby dissipating
the signal from the true causal variants.27
In addition to the strength of association between geno-
type and phenotype, an orthogonal source of information
lies within a variant’s functional genomic context. Projects
such as ENCODE29 and ROADMAP30 have provided a rich
atlas of functional information, and numerous groups
have reproducibly demonstrated that disease-associated
variants are systematically enriched within chromatin
marks that delineate active regulatory regions in phenotyp-
ically relevant cell types.31–35 Whereas functional genomic
data are often used as a post hoc validation of association
findings,4,10,36 a number of principled approaches have
been proposed to jointly integrate functional and associa-
tion data.28,35,37,38 In addition to increasing the accuracy
of fine mapping, these integrative approaches also provide
insights into the genetic architecture of the trait by identi-
fying relevant tissue-specific functional marks withouteles, Los Angeles, CA 90095, USA; 2Department of Human Genetics, David
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Figure 1. Example of a Fine-Mapping Locus in Three Different Populations
In population 1 (left), the causal variants are present, but strong regional LDmakes it difficult to distinguish them from tagging SNPs. In
population 2 (middle), the causal variants both have a very low frequency and/or are monomorphic, resulting in no observable associ-
ation between the SNPs and the trait. In population 3 (right), the causal variants are common and have few tagging SNPs. Our framework
jointly models population-specific LD structure and integrates functional genomic data to prioritize causal variants.making any prior assumptions. However, to the best of our
knowledge, functional integrative approaches have not
been extended to trans-ethnic finemapping, and a rigorous
assessment of trans-ethnic fine mapping in the presence of
multiple causal variants is currently lacking. Although in
principle the single-population frameworks that allow for
multiple causal variants27,28 can operate directly on trans-
ethnic meta-analysis statistics, they require ad hoc aver-
aging of trans-ethnic LD and do not properly account for
heterogeneity by ancestry at causal variants.
In this work, we propose a statistical framework that inte-
grates three sources of information to triangulate causal var-
iants infine-mapping studies: (1) the strengthof association
between genotype and phenotype, (2) differential genomic
background across ethnic groups, and (3) tissue-specific
functional genomic annotations (Figure 1). Different allele
frequencies (or sample sizes) across populations induce dif-
ferential standardized effect sizes at all the variants in a re-
gion, even in the presence of no allelic effect-size heteroge-
neity by ancestry. We model this induced heterogeneity
across populations through a multivariate normal (MVN)
framework wherein the sets of population-specific associa-
tion statistics are realizations from population-specific
MVN distributions. Similar to the case of a single popula-
tion,27,28 this allows us to consider multiple causal variants
at any risk locus. We integrate functional genomic data by
using Empirical Bayes,28 which provides a means of select-
ing functional annotations most relevant to the trait of in-
terest. Most importantly, our proposed approach requires
only the summary association data for each population,
thereby avoiding themany restrictions that can accompany
analysis of individual-level genotype data.
Through extensive simulations, we show that our trans-
ethnic framework significantly improves fine-mapping res-
olution over conventional meta-analysis strategies and
demonstrate that considering multiple causal variants in
multi-ethnic cohorts yields large gains in fine-mapping effi-
ciency. We showcase our framework by reanalyzing empir-
ical summary data from a large trans-ethnic rheumatoidThe Amerarthritis (RA [OMIM: 180300]) GWAS.4 We first demon-
strate that the functional architecture of RA is consistent
across ethnicities and that there is a strong preponderance
of immune-related functional classes that are enriched
with causal variants. We then fine map the RA GWAS loci
by using functional data and show that our method greatly
outperforms current state-of-the art methodologies and
uncovers a number of plausible functional variants.Material and Methods
Multi-population Fine-Mapping Framework
Without loss of generality (given that similar results can be derived
for case-control traits), let y be a quantitative phenotype such that
yi ¼ gibþ ei, where ei  Nð0; s2e Þ, and gi denotes a multi-SNP geno-
type containing {0,1,2} counts of the reference allele atM SNPs for
an individual i. The b vector represents allelic effects where the jth
entry will be non-zero only if SNP j is causal. Given genotype (Gp)
and phenotype (Yp) data over Np individuals from population p, a
standard approach to measuring association strength at SNP j is
through the Wald statistic
zjp ¼
bbjp
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We denote the non-centrality parameter (NCP) of the normal
distribution as
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Under the null hypothesis that SNP j is not causal (or does not
tag a causal variant; see below), b
j
p ¼ 0 and thus ljp ¼ 0. If the
SNP is causal, then b
j
ps0, yielding a non-zero l
j
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the power of detecting this variant in an association study (i.e., re-
jecting the null at some confidence level). Importantly, evenwhen
the allelic effects at the causal variants are similar across popula-
tions (i.e., b
j
p ¼ bjp0 ), different allele frequencies and sample sizes
induce population-specific NCPs, yielding larger NCPs at more
common SNPs and/or larger studies. This leads to the well-known
result that causal variants are more readily detectable in popula-
tions in which they are present more frequently.
Pervasive LD at fine-scale resolutions induces correlations be-
tweentagSNPsandcausalSNPs, thuscreatinganindirectassociation
between tag SNPs and traits.13 More specifically, the LD-induced
NCP at a SNP j ðLjpÞ can be approximated as a linear combination
of NCPs at the causal SNPs with LD-adjusted weights13,27,28,39 as
Ljp ¼
X
c
rj;cp l
c
p; (Equation 1)
where the sum is taken across all causal SNPs c, and r
j;c
p is the Pear-
son correlation coefficient between SNPs j and c in population p.
We expand Equation 1 to include all SNPs in the locus by incorpo-
rating indicator variable Ckp, which is set to 1 if SNP k is causal in
population p and 0 otherwise:
Ljp ¼
XM
k¼1
rj;kp l
k
pC
k
p: (Equation 2)
In vector notation,
Lp ¼ Sp

lp+Cp

; (Equation 3)
where Sp is the LD matrix of Pearson correlations among the M
SNPs, Cp is a binary vector indicating which SNPs are causal,
and + denotes the element-wise multiplication between two vec-
tors. We can now write the probability of the data (i.e., the
observed standardized effect sizes, Z scores) given the causal vari-
ants (Cp) in population p under a MVN assumption:
Zp j lp;Cp  N

Lp;Sp

: (Equation 4)
This allows us to define the total likelihood of the data by
marginalizing across all sets of causal SNPs (C) as
LðZ1;Z2;/;ZP ; l1; l2;/; lPÞ ¼
Y
p
X
Cp˛C
P

Zp j lp;Cp

P

Cp

;
(Equation 5)
which we simplify under the assumption that the causal vector set
is identical across populations:
LðZ1;Z2;/;ZP ; l1; l2;/; lPÞ ¼
X
C˛C
Y
p
P

Zp j lp;C

PðCÞ:
(Equation 6)
Here, PðZp
lp;CpÞ is defined as the probability density function
of the MVN (see Equation 4), and PðCÞ is the probability of a given
causal set. Note that Equation 6 assumes that the causal set is iden-
tical across populations but allows for different effect sizes at
causal SNPs across populations.
Integration of Functional-Annotation Data
We assume that each variant can potentially have several pheno-
typically relevant genomic functional annotations (e.g., transcrip-
tion factor binding site), which can be encoded as binary variable
Ajk for variant j and annotation k or as a continuous value (e.g.,
a probabilistic membership of variants in different functional
classes). We integrate the functional information through the
probability of the causal set C as follows,262 The American Journal of Human Genetics 97, 260–271, August 6PðC;gÞ ¼
Y 1
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where g is a vector containing the prior log-odds ratio of causality
for every functional annotation. We extend the likelihood to
incorporate functional data as
LðZ1;Z2;/;ZP ; l1; l2;/; lP ;gÞ ¼
X
C˛C
Y
p
P

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
PðC;gÞ;
(Equation 8)
which we can further simplify by assuming that data at different
loci are independent:
LðZ1;Z2;/;ZP ; l1; l2;/; lP ;gÞ ¼
Y
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Finally, to obtain posterior probabilities that each SNP is causal,
we use Bayes theorem to compute the joint posterior for each
causal set,
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and subsequently marginalize across all Cl ¼ ðC1l;C2l;.;CNl Þ such
that Cjl ¼ 1:
P

Cjl jZ1;Z2;/;ZP ; ll;1; ll;2;/; ll;P ;g
 ¼X
Cl˛Cl :Cjl¼1
PðCl jZ1;Z2;/;ZP ; ll;1; ll;2;/; ll;P;gÞ: (Equation 11)
Model Fitting
Because of the finite nature of either the sample or the reference
panel, the LDmatrix in practice could be ill conditioned.We apply
a Tikhonov Regularization40 to all LD matrices to ensure their in-
vertibility and as a result preserve the non-degeneracy and numer-
ical stability of the MVN approximation. Furthermore, because we
ensure that all S are positive definite, there exists a Cholesky
decomposition for each LD matrix and its corresponding inverse.
Let Lp ¼ CholðSpÞ1; it follows that eZp ¼ LpZp  NðLpLp; IÞ. In
practice, we operate in the transformed-Z-score space ð eZpÞ because
it improves numerical stability and reduces computational burden
by removing a large, repetitive matrix multiplication when
computing the MVN density.
We fit the parameters of the model to the data across all loci by
using a variant of the expectation maximization over the func-
tional annotations (g) and approximate the NCPs by using a sim-
ple function of the observed Z scores (see Appendix A). We note
that because enumerating over all possible causal sets is combina-
torially intractable, we typically restrict the number of causal var-
iants per locus to two or three in practice.
Simulation Data
We benchmarked our proposed framework by using simulations
starting from real genotype data. Using the NHGRI catalog of
GWAS variants on chromosome 1,1 we centered 25-kb windows
on the lead SNP and used HAPGEN241 and 1000 Genomes12 to
simulate individuals from the Asian (n ¼ 286), African (n ¼ 246),
and European (n ¼ 379) ancestries. SNPs that were polymorphic
with a minor allele frequency R 0.01 in at least one population, 2015
were retained for analysis. For each simulation, we randomly chose
50 loci and simulated causal variants by drawing causal status ac-
cording to the logistic prior model described above. Unless other-
wisenoted,weused the annotations (coding,UTR,promoter,DNase
hypersensitivity site [DHS], intronic, and intergenic) and functional
enrichments (13.83, 8.43, 2.83, 5.13, and0.13) observed inGusev
et al.35 for simulations below. We simulated phenotypes under a
linearmodel such that for individual i of population p, their pheno-
type Y was drawn as Yi;p ¼
PNc
j¼1bj,gj;i;p þ ei;p, where Nc is the total
number of causal variants, bj is the effect size of the j
th causal SNP,
gj;i;p is the number of copies of the risk allele j for individual i of pop-
ulation p. Following recent works, we simulated similar heritability
across populations.42 The population-specific error term, ei;p, was
drawn according to a Nð0; s2e;pÞ, where s2e;p ¼ ðs2g;p  h2g  s2g;pÞ=h2g ,
s2g;p ¼ b0CovðXpÞb, and CovðXpÞ is the population-specific covari-
ance of the genotypes (LD). The effect size, bj, was set to be inversely
proportional to the average SD of the population allele frequencies;
this is roughly equivalent to assuming that each causal SNPexplains
an equal proportion of the phenotypic variance.43
Existing Methods
We compared our proposed methods with other well-established
probabilistic methods for fine mapping. First, we investigated
MANTRA, a Bayesian trans-ethnic meta-analysis technique pro-
posed by Morris.15 We obtained the software implementation from
the author and ran it with the default settings; we provided the fixa-
tion index (FST) between the three populations as determined in
Nelis et al.44 as theprior for theBayesianpartitionmodel.Theoutput
of MANTRA is a Bayes factor, which we subsequently converted to
PPAi ¼ BFiP
kBFk
as previously recommended.3,22,45 Similarly, we calculated poste-
rior probabilities that SNPs are causal strictly on the basis of the in-
verse-variance fixed-effects19 meta-analysis by using the PAINTOR
(Probabilistic Annotation Integrator)28 and CAVIARBF46 frame-
works. We note that the CAVIARBF and PAINTOR models require
LD as input, which we calculated as the average of the population-
specific LD weighted by the sample size of each population.We as-
sessed accuracy by rank ordering SNPs across all fine-mapping loci
according to the output of each method and then determined the
proportion of identified causal variants as more SNPs were
selected. We typically report the median number of SNPs one
would need to validate in order to resolve 90% of the causal vari-
ants as our main metric of accuracy.
RA Multi-ethnic Fine-Mapping Dataset
We downloaded summary statistics from a large trans-ethnic RA
GWAS consisting of over 100,000 individuals (~68,000 of European
ancestry and ~36,000 of Asian ancestry).4 We used the reported
genome-wide-significant loci, excluding human leukocyte antigen
regions, and centered 100-kbwindows around the top SNP, yielding
a total of 89 fine-mapping loci. For each of these regions, we esti-
mated LD by using the European and Asian individuals from 1000
Genomes.12 We integrated 482 publicly available functional anno-
tations comprising 406 DHSs spanning numerous cell types and
tissues,31,47 the seven genomic segmentations of the eight primary
ENCODE cell lines,48 Fantom5 enhancer and transcription start
site regions,49 immune cell enhancers,10 genic elements derived
from GenCode,50 and overall methylation and acetylation marksThe Amerfrom ENCODE.29 The construction of a phenotypically specific
fine-mapping model requires two phases. First, we ran the model
marginally on each annotation and subsequently rank ordered all
the annotations according to likelihood-ratio statistics.28,37 Second,
weselected the topannotations thatwereminimallycorrelatedwith
one another (usually no more than five) to enter a final model to
estimate posterior probabilities that variants are causal.Results
Joint Modeling of Association Statistics across
Populations Increases Fine-Mapping Performance
We used simulations to investigate the benefit of jointly
modeling population-specific association statistics versus
standard meta-analysis approaches. We simulated fine-
mapping datasets over 10,000 individuals equally divided
among European, Asian, and African ancestries with total
heritability of h2g ¼ 0:25 across 50 loci with genetic archi-
tecture similar to that in Gusev et al.35 The loci were simu-
lated such that in expectation, each locus harbored a single
causal variant with allelic effects shared across populations
(see Material and Methods). This yielded an average of 15
loci with a single causal variant and 13 loci with multiple
causal variants per simulation. In general, we find that
trans-ethnic fine-mapping strategies that assume a single
causal variant are less optimal than those that allow for
multiple causal variants (Table 1). For example, MANTRA
meta-analysis requires 1.9 and 96.8 SNPs per locus in order
to identify 50% and 90% of the causal variants, respec-
tively, whereas methods that allowmultiple causal variants
but do not incorporate functional data require 1.2 and 7.0
SNPs per locus to identify 50% and 90% of the causal var-
iants, respectively.46 Existing integrative fine-mapping
methods that leverage functional data28 applied to fixed-
effects meta-analysis statistics achieve accuracy of 1.0
and 5.6 SNPs per locus to find 50% and 90% of the causal
variants, respectively. In contrast, our proposed framework
resolves causal variants with the greatest efficiency
(Figure 2) in that it requires only 0.9 and 5.2 SNPs per locus
to find 50% and 90% of the causal variants, respectively
(paired t test, p < 0.001). Overall, this can be attributed
to the fact that our approach models population-specific
LD patterns while allowing for multiple causal variants in
the presence of functional information.
Recent studies have shown that GWAS findings generally
replicate across populations,42,51 thus suggesting sharing of
underlying causal variants. However, it is generally un-
known whether these variants contribute to disease risk
uniformly across populations. We sought to assess the per-
formance of finemapping in the situation where the causal
variants have either weak or strong heterogeneity by
ancestry. In addition to fine mapping datasets in which
causal effects were similar across populations (no heteroge-
neity), we simulated allelic effects inversely proportional to
thepopulation-specific allele-frequency SD (weakheteroge-
neity) and normally distributed allelic effects for each
ancestry independently (strong heterogeneity). We foundican Journal of Human Genetics 97, 260–271, August 6, 2015 263
Table 1. Our Trans-ethnic Integrative Framework Is Superior to Conventional Meta-analysis Strategies and Current State-of-the-Art
Methodologies
Heterogeneity
Level
Identified Proportion
of Causal Variants
Single Causal Variant per Locus Multiple Causal Variants per Locus
Fixed-Effects
Meta-analysis MANTRA15
Fixed-Effects
CAVIARBF46
Fixed-Effects
PAINTOR28,a
Trans-ethnic
PAINTORa
None 0.50 1.9 2.0 1.2 1.0 0.9
0.75 29.8 30.3 2.9 2.1 1.9
0.90 96.8 96.8 7.0 5.6 5.2
Weak 0.50 1.9 2.0 1.1 0.9 0.9
0.75 62.3 62.7 2.9 2.0 1.8
0.90 118.1 118.6 6.8 4.9 4.1
Strong 0.50 29.0 11.1 12.6 9.6 2.3
0.75 105.0 92.7 68.6 58.4 19.7
0.90 143.9 139.8 134.4 121.3 56.5
We simulated 1,000 multi-ethnic fine-mapping datasets under various levels of allelic heterogeneity across populations. For the first two levels of heterogeneity
(‘‘none’’ and ‘‘weak’’), we invoked the standard infinitesimal assumption on allelic effects either globally or at the population level by setting effect sizes ðbc;pÞ at the
causal SNPs inversely proportional to either the mean allele-frequency SD or the population-specific allele-frequency SD. To simulate strong heterogeneity across
ancestries, we drew effect sizes from a standard normal distribution for each population independently and added enough Gaussian noise to maintain h2g ¼ 0:25.
Displayed here is the median number of SNPs selected per locus for identifying a specified proportion of the causal variants.
aMethods that also integrate functional data.that our framework significantly outperformed the fixed-ef-
fects meta-analysis followed by probability estimation by
existing methods. For example, in the case of weak hetero-
geneity, our approach required 4.1 as opposed to 4.9 SNPs
per locus (19.5% improvement); in addition, in the pres-
ence of strong heterogeneity, our approach dramatically
outperformed existingmeta-analysis strategies by reducing
the number of SNPs required for identifying 90% of the
causal variants from 121.3 to 56.5 (214% improvement)
(Table 1; Figure 2). The increase in performance is likely
due to the fact that our framework makes no assumptions
pertaining to the population-specific allelic effects at causal
SNPs, given that we allow the empirically observed Z scores
in each population to dictate the effect size. This allows for
arbitrary levels of heterogeneity in the effect size by popula-
tion,whereas fixed-effectsmeta-analysis assumes similar ef-
fect sizes across populations.Figure 2. Trans-ethnic PAINTOR Is Most Efficient in Identifying Ca
The distributions of the number of SNPs required for follow-up ident
displayed as boxplots. The different panels represent increasing levels
and strong (right). The widths of the notches in each boxplot roughly
SNPs required for resolving 90% of the causal variants. For the sake o
ence in performance across all three methods.
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The benefit of trans-ethnic fine mapping has been thor-
oughly documented both in simulations and in empirical
data.3,13,15 However, previous works have assumed a single
causal variant at a risk locus, and this assumption is often in-
validated in practice. Here, we sought to assess trans-ethnic
finemapping in thepresence ofmultiple causal variants at a
risk locus while integrating functional-annotation data.
Consistent with previous works,13 we found that for the
same sample size,multi-ethnic cohorts attained superior ac-
curacy over single-population studies. However, allowing
for multiple causal variants enabled trans-ethnic fine map-
ping to perform even better than single-population fine
mapping. We observed a near 3- to 4-fold increase in the
median resolution for methods that model multiple causal
variants but only a 1.4- to 1.6-fold gain formethods that as-
sume a single causal (see Table 2). We attribute this to theusal Variants
ification of 90% of the causal variants across 1,000 simulations are
of effect-size heterogeneity by ancestry: none (left), weak (middle),
correspond to 95% confidence intervals for themedian number of
f clarity, we have cut the y axis to emphasize the significant differ-
, 2015
Table 2. Modeling Multiple Causal Variants in Multi-ethnic
Cohorts Yields Larger Relative Gains in Fine-Mapping Efficiency
Ethnic
Group
Single Causal Variant Multiple Causal Variants
 þ  þ
Asians 136.9 134.4 89.3 36.2
Europeans 135.0 130.9 82.9 33.5
Africans 104.0 95.0 34.4 14.7
Trans-ethnic 72.6 58.4 8.5 4.9
Relative 1.4 1.6 4.0 3.0
We simulated fine-mapping datasets with various ethnic compositions and
allelic effects shared across populations. Displayed here are four fine-mapping
strategies that consider either single or multiple causal variants at each risk lo-
cus and either have (þ) or do not have () access to functional data across
different ethnic study designs. The bottom row represents the relative gain
in the median 90% causal-variant resolution of trans-ethnic cohorts over the
next best-performing group.much smaller number of sets of causal variants (as a propor-
tion of the total possible sets) that are compatible with the
observed association statistics. Diversity in LD patterns
across populations additionally penalizes sets of variants
that do not contain the true causal variants because they
are unlikely to explain the observed data. Consequently,
multi-ethnic cohorts not only will have proportionally
moreLDpatterns than single-populationcohorts (therefore
placing larger penalties on incorrect causal sets) but can also
borrow power from populations where the causal variants
are present more frequently.
Genetic-Trait Architecture Affects Fine-Mapping
Performance
Functional information was demonstrated to improve
fine-mapping resolution in a single population,10,28,37,38
and we investigated the potential gains in a trans-ethnicThe Amersetting. We simulated two disease architectures by using
five functional annotations where causal variants either
localize predominantly within a single broad functional
class, as observed by Gusev et al.35 (A1), or have a smaller,
more diffuse localization within functionally specific cell
types28 (A2). For each class of disease architectures, we fit
six trans-ethnic integrative models such that each succes-
sive model incorporated an additional functional annota-
tion into a joint framework. Not surprisingly, when the
true genetic architecture of a trait at fine-mapping regions
has a strong enrichment of causal variants within a com-
mon functional class (i.e., DHSs35), these functional anno-
tations will be most informative for the purposes of fine
mapping (see Figure 3). On the other hand, more diffuse
localization of causal variants requires multiple annota-
tions for maximizing the utility of functional data. For
example, for genetic architecture A1, the addition of the
DHS annotation yielded a 70% increase in fine-mapping
resolution, whereas genetic architecture A2 required all
five annotations to improve resolution by 18% (see
Figure 3).Integrative FineMapping in aMulti-ethnic RADataset
We investigated whether similar results from simulations
can be attained in empirical data from a trans-ethnic RA
GWAS over more than 100,000 individuals4 (see Material
and Methods). Because the functional genetic architecture
of RA across different populations is unknown, we first
quantified whether the enrichment of causal variants in
various functional annotations is consistent across ances-
tries. Reassuringly, we saw a strong correspondence in func-
tional enrichment at the fine-mapping loci across all 482
functional categories we investigated (r ¼ 0.597; Figure 4).
This provides evidence supporting the assumption that aFigure 3. The Underlying Functional Ar-
chitecture of a Trait Affects Fine-Mapping
Performance
We simulated two classes of disease archi-
tectures: A1 (solid line) and A2 (dashed
line). Architecture A1 was based on the
functional enrichment observed in Gusev
et al.35 and had a strong enrichment
within a single DHS class. Architecture A2
was simulated with a more diffuse enrich-
ment in various cell types and classes
and was based on what we empirically
observed in the RA dataset. Displayed on
top of each point is the percentage of
SNPs falling within that annotation and
its corresponding enrichment.
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Figure 4. Functional Enrichment Is Consistent across Europeans
and Asians
Wecompared the enrichment across 482 functional annotations at
89 RA-associated loci in Europeans (nz 68,000) and Asians (nz
36,000) separately. Eachpoint represents theestimatedenrichment
of an annotation in both European and Asian populations.
Figure 5. Trans-ethnic Functional Enrichment at RA GWAS Loci
Indicates Immune-Related Regulatory Architecture
Here, we compare the enrichment of casual variants within 42
DHSs of immune-related cell types (B cells, T cells, natural killer
cells, keratinocytes, monocytes, and thymic cells) and the enrich-
ment of causal variants in 354 DHS annotations of other cell types.
The widths of the notches in each boxplot roughly correspond to
95% confidence intervals for the median enrichment.single functional prior can be applied across populations
uniformly in trans-ethnic fine mapping.
Next, we estimated trans-ethnic enrichment for each of
the 482 annotations independently to allow the model to
discern themost functionally relevant cell types andclasses.
Theenrichment likelihood ratios suppliedby thisprocedure
provideanaturalway toprioritize functional annotations to
move forward with fine mapping.28 We consistently found
a strong and significant enrichment of causal variants
within activity regulatory regions of immune-related cell
types (see Figure 5), which is largely in linewith RA etiology
(rank permutation p < 0.001). The final trans-ethnic inte-
grativemodel included annotations of DHS regions specific
to three cell types (skin keratinocytes, T helper 2 cells, and
B lymphocytes), immune enhancer regions described in
Farh et al.,10 and GENCODE-defined exon regions. We
found that simply applying existing multi-causal frame-
works27,28 on the trans-ethnic meta-analysis statistics
yielded wider 90% credible sets (it required approximately
28.5 SNPs per locus as opposed to 24.0 SNPs per locus for
our proposed framework), thus demonstrating the benefit
ofmodeling population-level LD. Furthermore, the integra-
tion of functional data additionally reduced the size of the
credible set to 21.7 SNPs per locus (see Table 3), showing
that leveraging functional annotations refines trans-ethnic
fine-mapping signal.
Next, we explored the plausible causality of the SNPs
that attained a high posterior probability under our frame-
work (Table 4). For example, rs968567, which lies within
the promoter region of FADS2 (OMIM: 606149) and was
functionally validated to disrupt transcription factor
binding and subsequent gene expression,52 achieved a
trans-ethnic posterior probability of 0.29. However, this
variant fell within all five functional annotations that266 The American Journal of Human Genetics 97, 260–271, August 6our framework deemed important for this trait and,
upon appropriate re-weighting, achieved a posterior
probability of 0.84. Alternatively, trans-ethnic association
can be extremely beneficial on its own. For example,
rs12693993, a variant within the coding region of CD28
(OMIM: 186760), a gene implicated for its importance in
T cell development and proliferation and cytokine produc-
tion, achieved a posterior probability for causality of 0.34
and 0.02 in Europeans and Asians, respectively. However,
upon integration of trans-ethnic association with func-
tional data, it achieved a posterior probability for causality
of 0.85. The identification of these two SNPs, among
others, serves as an important illustration of the benefit
of our proposed methodologies.Discussion
In this work, we introduced a fine-mapping framework
that bridges several sources of evidence to prioritize func-
tional SNPs and demonstrated its efficacy in real and simu-
lated datasets. As fine-mapping data become increasingly
multi-ethnic3,4 and functional data become larger and
more refined,30 we believe that our proposed methodology
will have increasing relevance. By operating exclusively on
summary data, our approach reduces the need to share in-
dividual data, which often prohibits large-scale analyses.
In addition, a key advantage of our proposed methodology
is that it provides an unbiased perspective on which func-
tional genomic data aremost relevant to the trait within an
Empirical Bayes framework. Rather than relying on careful
and manual selection of functional elements when con-
ducting fine mapping,10,36 we allow the data to dictate, 2015
Table 3. Integrative Approaches that Model Population-Level LD
Yield the Smallest Credible Sets in Empirical Data
Association Statistics
Average No. of SNPs
Without
Annotations
With
Annotations
Asians 35.2 31.9
Europeans 32.0 28.7
Fixed-effects meta-analysis 28.5 25.0
Trans-ethnic 24.0 21.7
Displayed here is the average number of SNPs per locus in the 90% credible
sets for single and multi-population fine mapping of RA-associated loci. To
compute credible sets, we first ordered the SNPs across all 89 loci and then
took the total number of ordered SNPs that consumed 90% of the total poste-
rior probability mass. Consistent with simulation findings, integrating multiple
populations with functional data improved fine-mapping resolution.the functional relevance of a particular annotation. As the
catalog of functional data expands to encompass more
diverse cell types and genomic signatures, a principled
strategy to parsing these annotations is paramount.
We note that although our model does not assume a pri-
ori that there exists allelic heterogeneity by ancestry,15 by
construction, it is capable of handling trans-ethnic hetero-
geneity whether it is due to a true difference in the per-
allelic effects or simply a result of genetic drift that yielded
distinct allele frequencies at the causal SNPs. We have
found that as the level of heterogeneity across popula-
tions increases, our framework increasingly outperformsTable 4. Integrating Trans-ethnic Association Strength with Function
Probability for Causality
rsID
Chromosomal
Position
European
Association
(Z Score)
Asian
Association
(Z Score)
Posterior
Probabilit
without
Annotatio
rs2476601 chr1: 114,377,568 26.04 NA 1.00
rs7731626 chr5: 55,444,683 9.84 NA 1.00
NA chr1: 2,523,878 5.22 4.18 1.00
rs1893592 chr21: 43,855,067 5.73 4.01 1.00
NA chr19: 10,771,941 6.13 NA 1.00
rs72767222 chr5: 55,440,788 5.11 NA 0.99
rs12715125 chr3: 27,763,427 5.58 NA 0.95
rs71508903 chr10: 63,779,871 7.26 5.88 0.76
rs12693993 chr2: 204,595,597 2.74 1.76 0.68
rs968567 chr11: 61,595,564 4.95 NA 0.29
rs909685 chr22: 39,747,671 6.29 4.62 0.65
rs657075 chr5: 131,430,118 2.54 4.46 0.73
We applied our framework across all 89 GWAS RA loci with relevant functional dat
of greater than 0.8. Abbreviations are as follows: NA, not applicable; Th2, T help
The Amercompeting strategies. Although extreme heterogeneity
might be unlikely, gene-environment interactions in com-
plex traits canmanifest themselves as distinct allelic effects
across populations.53
We conclude with several limitations of our proposed
framework. The efficacy of our proposed method is inti-
mately connected to the underlying functional architec-
ture of the trait being examined. In the scenario where
the correct functional annotation is unavailable or the
distribution of casual variants is more or less uniform
across the functional-annotation categories, our method
will most likely underperform fine-mapping strategies
that either do not estimate parameters for functional
enrichment27,46 or pre-specify the correct enrichment pa-
rameters from other external analyses.35 However, there
is mounting evidence that suggests that casual variants
for most complex traits co-localize with epigenetic
marks10,31,35,37 that are now available for the vast majority
of human cell types.54 Finally, additional improvements in
performance could be made through a Bayesian treatment
of non-centrality parameters within our framework,46
which we leave as a potential direction for future work.Appendix A: Optimization Procedure
We optimize the parameters of our model by using expec-
tation maximization. First, we take expectations of the
complete data log-likelihood with respect to the posterioral Data Promotes a Number of SNPs to Attain a High Posterior
y
ns
Posterior
Probability with
Annotations Functional Annotations
1.00 coding exons, skin keratinocyte DHSs
1.00 GM12865 DHSs, Th2 DHSs, immune
enhancers
1.00 immune enhancers
1.00 coding exons, immune enhancers
1.00 immune enhancers
0.99 skin keratinocyte DHSs, immune enhancers
0.99 coding exons, GM12865 DHSs, Th2 DHSs,
skin keratinocyte DHSs, immune enhancers
0.93 GM12865 DHSs, skin keratinocyte DHSs,
immune enhancers
0.88 Th2 DHSs, skin keratinocyte DHS, immune
enhancers
0.85 coding exons, GM12865 DHSs, Th2 DHSs,
skin keratinocyte DHSs, immune enhancers
0.84 Th2 DHSs, skin keratinocyte DHSs, immune
enhancers
0.82 skin keratinocyte DHSs, immune enhancers
a. Displayed in this table are SNPs achieving a trans-ethnic posterior probability
er 2 cell.
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distribution of causal sets and simplify to obtain a func-
tion, Q, that is readily optimized via standard techniques.
Let Zl; represent all P vectors of association statistics
ðZl;1;Zl;2;/;Zl;PÞ at locus l, and let ll; be the corresponding
vectors of non-centrality parameters,Q

g; l jgðtÞ; l ¼X
l
X
Cl
P

Cl jZl;ll;;gðtÞ

ln P

Zl;; ll;;g
ðtÞ
¼P
l
P
Cl
P

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
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ln P

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l
P
Cl
P

Cl jZl;ll;;gðtÞ

ln P

Cl;g
ðtÞþX
l
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Cl
P

Cl jZl;;gðtÞ; ll;
X
p
ln P

Zl;p jCl; ll;p

¼ Qg jgðtÞþ Qlp j lp;thereby decoupling the prior from the likelihood. We
simplify QðggðtÞÞ to obtain
Q

g jgðtÞ; l ¼X
l
X
j
X
cjl˛0;1
P

cjl jZl;;gðtÞ; ll;

ln P

cjl;g
ðtÞ
¼ P
l
P
j
P

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
ln

1þ expgTAjl
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l
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
ln
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1þ expgTAjl;
which is a concave function whose gradient is simplyvQ

g jgðtÞ; l
vg
¼
X
j
X
l
P

cjl ¼ 1 jZl;;gðtÞ; ll;
 1
1þ expgTAjlAjl

X
j
X
l
P

cjl ¼ 0 jZl;;gðtÞ; ll;
 1
1þ expgTAjlAjl:To avoid potential numerical instability resulting from
inverting a Hessian matrix, as would be required for stan-
dard Newton-Raphson, we optimize this function Q
by using a limited-memory Broyden-Fletcher-Goldfarb-
Shanno algorithm implemented in the NLopt library.
Finally, as previously mentioned, the non-centrality
parameter for SNP j at locus l from population p, l
j
p;l, is
set simply asf

Zjp;l

¼
8>><>>:
arg min

 3:7;Zjp;l

ifZjp;l < 0
arg max

3:7;Zjp;l

ifZjp;l > 0
0 if Zjp;l ¼ 0 ðSNP j is monomorphic in population pÞ;a strategy that was previously demonstrated to work well
in practice.28 This iterative algorithm is repeated until the
change in the log-likelihood is less than 0.01.268 The American Journal of Human Genetics 97, 260–271, August 6Acknowledgments
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